The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee
Abstract
Purpose: Identifying pathobiological correlates of clinical behavior or therapeutic response currently represents a key challenge for medulloblastoma research. Nuclear accumulation of the β-catenin protein is associated with activation of the Wnt/Wg signaling pathway, and mutations affecting components of this pathway have been reported in approximately 15% of sporadic medulloblastomas. We tested the hypothesis that nuclear immunoreactivity for β-catenin is a prognostic marker in medulloblastoma, and assessed the relationship between nuclear β-catenin immunoreactivity and mutations of CTNNB1 and APC. Patients and Methods: Medulloblastomas from children entered onto the International Society for Pediatric Oncology (SIOP)/United Kingdom Children's Cancer Study Group (UKCCSG) PNET3 trial (n = 109) were examined for β-catenin immunoreactivity, and where tissue was available, evidence of CTNNB1 and APC mutations. The results were correlated with clinicopathologic variables, principally outcome. Results: Children with medulloblastomas that showed a nucleopositive β-catenin immunophenotype (27 of 109; 25%) had significantly better overall (OS) and event-free (EFS) survivals than children with tumors that showed either membranous/cytoplasmic β-catenin immunoreactivity or no immunoreactivity (P = .0015 and P = .0026, respectively). For β-catenin nucleopositive and nucleonegative medulloblastomas, 5-year OS was 92.3% (95% CI, 82% to 100%) versus 65.3% (95% CI, 54.8 to 75.7%), and 5-year EFS was 88.9% (95% CI, 77% to 100%) versus 59.5% (95% CI, 48.8 to 70.2%), respectively. Mutations in CTNNB1 were found exclusively among medulloblastomas that demonstrated nuclear β-catenin immunoreactivity, but no evidence of APC mutation was found in these cases. All children with β-catenin nucleopositive large cell/anaplastic medulloblastomas and β-catenin nucleopositive medulloblastomas presenting with metastatic disease are alive at least 5 years postdiagnosis. Conclusion: Nuclear accumulation of β-catenin appears to be a marker of favorable outcome in medulloblastoma, and should be investigated further in large group-wide trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer
Suzuki, H., Watkins, D. N., Jair, K.-W., Schuebel, K. E., Markowitz, S. D., Dong Chen, W., Pretlow, T. P., Yang, B., Akiyama, Y., van Engeland, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1330 · Cited by 1,069
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,021
Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., et al. (2000) · Nature Genetics · doi:10.1038/73448 · Cited by 960
Fearnhead, N. S. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.721 · Cited by 882
Late neurocognitive sequelae in survivors of brain tumours in childhood
Mulhern, R. K., Merchant, T. E., Gajjar, A., Reddick, W. E., & Kun, L. E. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01507-4 · Cited by 872
Survival Analysis: A Practical Approach.
Smith, P. J., Parmar, M. K. B., & David, M. (1996) · Journal of the American Statistical Association · doi:10.2307/2291609 · Cited by 730
Zechner, D., Fujita, Y., Hülsken, J., Müller, T., Walther, I., Taketo, M. M., Bryan Crenshaw, E., Birchmeier, W., & Birchmeier, C. (2003) · Developmental Biology · doi:10.1016/s0012-1606(03)00123-4 · Cited by 483
Taylor, R. E., Bailey, C. C., Robinson, K., Weston, C. L., Ellison, D., Ironside, J., Lucraft, H., Gilbertson, R., Tait, D. M., Walker, D. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.116 · Cited by 353
Self-citationSharma, M., Chuang, W. W., & Sun, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201919200 · Cited by 308
Cited by
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
“Studies have shown that activation of the canonical Wnt signalling pathway is mainly evaluated by detecting the β-catenin immunophenotype, and methylation subgroups are consistent with IHC.231,249,250 The four DNA methylation subgroups of medulloblastoma in the study included Wnt, SHH, Group 3, and Group 4.”
BackgroundMolecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936
“The best known of the medulloblastoma subgroups is the Wnt subgroup due to its very good long-term prognosis in comparison to other subgroups [8, 11, 13, 15, 22, 28, 39, 48].”
BackgroundSelf-citationWNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
Medulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,339
Self-citationKool, M., Korshunov, A., Remke, M., Jones, D. T. W., Schlanstein, M., Northcott, P. A., Cho, Y.-J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0958-8 · Cited by 1,056
Self-citationGajjar, A., Chintagumpala, M., Ashley, D., Kellie, S., Kun, L. E., Merchant, T. E., Woo, S., Wheeler, G., Ahern, V., Krasin, M. J., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70867-1 · Cited by 951
Subtypes of medulloblastoma have distinct developmental origins
Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C., Kranenburg, T. A., Hogg, T., Poppleton, H., Martin, J., et al. (2010) · Nature · doi:10.1038/nature09587 · Cited by 831
Self-citationTargeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Huse, J. T., & Holland, E. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2818 · Cited by 763
Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N. S.-V., Caron, H. N., Cloos, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003088 · Cited by 722
Self-citationCho, Y.-J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5148 · Cited by 717
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S. C., Doz, F., Kool, M., Dufour, C., Vassal, G., Milde, T., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1569-6 · Cited by 654
Self-citationMedulloblastomics: the end of the beginning
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y.-J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3410 · Cited by 663
Northcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0063-6 · Cited by 649
Self-citationMedulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups
Ellison, D. W., Dalton, J., Kocak, M., Nicholson, S. L., Fraga, C., Neale, G., Kenney, A. M., Brat, D. J., Perry, A., Yong, W. H., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0800-8 · Cited by 563
Self-citationSchwalbe, E. C., Lindsey, J. C., Nakjang, S., Crosier, S., Smith, A. J., Hicks, D., Rafiee, G., Hill, R. M., Iliasova, A., Stone, T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30243-7 · Cited by 516
Self-citationMedulloblastoma Genotype Dictates Blood Brain Barrier Phenotype
Phoenix, T. N., Patmore, D. M., Boop, S., Boulos, N., Jacus, M. O., Patel, Y. T., Roussel, M. F., Finkelstein, D., Goumnerova, L., Perreault, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.002 · Cited by 353
Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., & Uhm, J. H. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1271 · Cited by 341
The clinical implications of medulloblastoma subgroups
Northcott, P. A., Korshunov, A., Pfister, S. M., & Taylor, M. D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.78 · Cited by 328
MRI Surrogates for Molecular Subgroups of Medulloblastoma
Perreault, S., Ramaswamy, V., Achrol, A. S., Chao, K., Liu, T. T., Shih, D., Remke, M., Schubert, S., Bouffet, E., Fisher, P. G., et al. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3990 · Cited by 328
Pollack, I. F., Agnihotri, S., & Broniscer, A. (2019) · Journal of Neurosurgery: Pediatrics · doi:10.3171/2018.10.peds18377 · Cited by 314
Cytogenetic Prognostication Within Medulloblastoma Subgroups
Shih, D. J. H., Northcott, P. A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., Yao, Y., Wang, X., Dubuc, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9539 · Cited by 313
Self-citationSharma, T., Schwalbe, E. C., Williamson, D., Sill, M., Hovestadt, V., Mynarek, M., Rutkowski, S., Robinson, G. W., Gajjar, A., Cavalli, F., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02020-0 · Cited by 310
Self-citationA Mouse Model of the Most Aggressive Subgroup of Human Medulloblastoma
Kawauchi, D., Robinson, G., Uziel, T., Gibson, P., Rehg, J., Gao, C., Finkelstein, D., Qu, C., Pounds, S., Ellison, D. W., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.023 · Cited by 305
Self-citationEllison, D. W., Kocak, M., Dalton, J., Megahed, H., Lusher, M. E., Ryan, S. L., Zhao, W., Nicholson, S. L., Taylor, R. E., Bailey, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2810 · Cited by 302
Self-citationThe Origins of Medulloblastoma Subtypes
Gilbertson, R. J., & Ellison, D. W. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151518 · Cited by 294
Self-citationPfister, S., Remke, M., Benner, A., Mendrzyk, F., Toedt, G., Felsberg, J., Wittmann, A., Devens, F., Gerber, N. U., Joos, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9432 · Cited by 293
Medulloblastomics revisited: biological and clinical insights from thousands of patients
Hovestadt, V., Ayrault, O., Swartling, F. J., Robinson, G. W., Pfister, S. M., & Northcott, P. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0223-8 · Cited by 271
Medulloblastoma in childhood: new biological advances
Crawford, J. R., MacDonald, T. J., & Packer, R. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70289-2 · Cited by 286
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., Mahajan, A., Su, J., Bouffet, E., Bartels, U., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01372 · Cited by 241
Self-citationHill, R. M., Kuijper, S., Lindsey, J. C., Petrie, K., Schwalbe, E. C., Barker, K., Boult, J. K. R., Williamson, D., Ahmad, Z., Hallsworth, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.002 · Cited by 210
Self-citationRole of MYC in medulloblastoma
Roussel, M. F., & Robinson, G. W. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014308 · Cited by 180
Gaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146
Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies
Wang, J., Garancher, A., Ramaswamy, V., & Wechsler-Reya, R. J. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-013838 · Cited by 113
Williamson, D., Schwalbe, E. C., Hicks, D., Aldinger, K. A., Lindsey, J. C., Crosier, S., Richardson, S., Goddard, J., Hill, R. M., Castle, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111162 · Cited by 87
Self-citation
Metadata
- Authors
- Ellison, D. W., Onilude, O. E., Lindsey, J. C., Lusher, M. E., Weston, C. L., Taylor, R. E., Pearson, A. D., & Clifford, S. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-11-01
- Volume
- 23
- Issue
- 31
- Pages
- 7951-7957
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139787372
- Cited by
- 435
- References
- 35
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.